File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Hyperlipidaemic effect of Janus kinase inhibitors: a meta-analysis
Title | Hyperlipidaemic effect of Janus kinase inhibitors: a meta-analysis |
---|---|
Authors | |
Issue Date | 2019 |
Publisher | Hong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/ |
Citation | 24th Medical Research Conference, Department of Medicine, The University of Hong Kong, Hong Kong, 19 January 2019. In Hong Kong Medical Journal, 2019, v. 25 n. 1, Suppl. 1, p. 40 How to Cite? |
Abstract | Introduction: Janus kinase (JAK) inhibitors are effective in treating rheumatoid arthritis. However, JAK is involved in lipid metabolism, so we investigated the association between JAK inhibitors and hyperlipidaemia.
Methods: We conducted a literature search using ISI Web of Science, Scopus, Medline, Cochrane library, Clinicaltrials.gov, and Embase. We included randomised controlled trials reporting the frequency of hypercholesterolaemia or hyperlipidaemia as a study outcome. Results were analysed using RevMan 5.3.5. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using a random effects model. The standardised mean differences (SMDs) and 95% CIs were estimated for the change in lipid profile.
Results: In all, 17 trials were included in the meta-analysis. Janus kinase inhibitors were associated with
hypercholesterolaemia (OR=2.52, 95% CI=1.59-3.99; I2 statistics: 0%) and hyperlipidaemia (OR=3.23, 95% CI=1.73-6.04; I2 statistics: 0%). Both JAK inhibitors were associated with increase in serum high-density lipoprotein level (baricitinib: SMD=1.60, 95% CI=0.67-2.53 mg/dL; tofacitinib: SMD=2.80, 95% CI=0.61-4.98 mg/dL) and low-density lipoprotein level (baricitinib: SMD=2.47, 95% CI=0.40-4.53 mg/dL; tofacitinib: SMD=2.79, 95% CI=1.17-4.41 mg/dL).
Conclusions: Janus kinase inhibitors increased serum low-density lipoprotein and high-density lipoprotein
levels. Significant associations between JAK inhibitors and hypercholesterolaemia as well as hyperlipidaemia were revealed. If causal, there would be important clinical implications for rheumatoid arthritis patients. |
Persistent Identifier | http://hdl.handle.net/10722/269506 |
ISSN | 2023 Impact Factor: 3.1 2023 SCImago Journal Rankings: 0.261 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tsoi, MF | - |
dc.contributor.author | Cheung, TT | - |
dc.contributor.author | Cheung, BMY | - |
dc.date.accessioned | 2019-04-24T08:09:04Z | - |
dc.date.available | 2019-04-24T08:09:04Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | 24th Medical Research Conference, Department of Medicine, The University of Hong Kong, Hong Kong, 19 January 2019. In Hong Kong Medical Journal, 2019, v. 25 n. 1, Suppl. 1, p. 40 | - |
dc.identifier.issn | 1024-2708 | - |
dc.identifier.uri | http://hdl.handle.net/10722/269506 | - |
dc.description.abstract | Introduction: Janus kinase (JAK) inhibitors are effective in treating rheumatoid arthritis. However, JAK is involved in lipid metabolism, so we investigated the association between JAK inhibitors and hyperlipidaemia. Methods: We conducted a literature search using ISI Web of Science, Scopus, Medline, Cochrane library, Clinicaltrials.gov, and Embase. We included randomised controlled trials reporting the frequency of hypercholesterolaemia or hyperlipidaemia as a study outcome. Results were analysed using RevMan 5.3.5. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using a random effects model. The standardised mean differences (SMDs) and 95% CIs were estimated for the change in lipid profile. Results: In all, 17 trials were included in the meta-analysis. Janus kinase inhibitors were associated with hypercholesterolaemia (OR=2.52, 95% CI=1.59-3.99; I2 statistics: 0%) and hyperlipidaemia (OR=3.23, 95% CI=1.73-6.04; I2 statistics: 0%). Both JAK inhibitors were associated with increase in serum high-density lipoprotein level (baricitinib: SMD=1.60, 95% CI=0.67-2.53 mg/dL; tofacitinib: SMD=2.80, 95% CI=0.61-4.98 mg/dL) and low-density lipoprotein level (baricitinib: SMD=2.47, 95% CI=0.40-4.53 mg/dL; tofacitinib: SMD=2.79, 95% CI=1.17-4.41 mg/dL). Conclusions: Janus kinase inhibitors increased serum low-density lipoprotein and high-density lipoprotein levels. Significant associations between JAK inhibitors and hypercholesterolaemia as well as hyperlipidaemia were revealed. If causal, there would be important clinical implications for rheumatoid arthritis patients. | - |
dc.language | eng | - |
dc.publisher | Hong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/ | - |
dc.relation.ispartof | Hong Kong Medical Journal | - |
dc.relation.ispartof | 24th Medical Research Confernece, Department of Medicine, The University of Hong Kong | - |
dc.rights | Hong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press. | - |
dc.title | Hyperlipidaemic effect of Janus kinase inhibitors: a meta-analysis | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Cheung, TT: tcheungt@hku.hk | - |
dc.identifier.email | Cheung, BMY: mycheung@hkucc.hku.hk | - |
dc.identifier.authority | Cheung, TT=rp01682 | - |
dc.identifier.authority | Cheung, BMY=rp01321 | - |
dc.identifier.hkuros | 297290 | - |
dc.identifier.volume | 25 | - |
dc.identifier.issue | 1, Suppl. 1 | - |
dc.identifier.spage | 40 | - |
dc.identifier.epage | 40 | - |
dc.publisher.place | Hong Kong | - |
dc.identifier.issnl | 1024-2708 | - |